Search - tctmd.com

Displaying 361 - 380 of 477

Sort: Relevancy | Date

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Presenter: Pascal Vranckx

October 31, 2013

Presentation TCT 2013

Critical Appraisal and Clinical Implications(3)

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

Clopidogrel Is Cheap, Effective, and Sufficient for Most!

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Presenter: Philippe Gabriel Steg

October 31, 2013

Presentation TCT 2013

Cangrelor Will Be the Answer for Most in the Acute Setting!

Presenter: Robert Harrington

October 31, 2013

Presentation TCT 2013

Cangrelor Properties: PK, PD and More

Presenter: Sergio Leonardi

October 31, 2013

Presentation TCT 2013

BRIDGE Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

A Patient with a Recent Stent Who is Bleeding

Presenter: Peter Wenaweser

October 31, 2013

News Conference News TCT 2013

OPTIMIZE: 3-Month DAPT Safe with ZES

October 31, 2013

Presentation TCT 2013

EUROMAX: Critical Appraisal and Clinical Implications

Presenter: Gregg Stone

October 30, 2013

Presentation TCT 2013

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Presenter: Matthew Price

October 30, 2013

Presentation TCT 2013

Featured Trial of the Day: EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin vs. Heparin ± Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI...

Presenter: Philippe Gabriel Steg

October 30, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-7. Impact Of Early Versus Late Clopidogrel Discontinuation On Stent Thrombosis Following Percutaneous Coronary Intervention With First- And Second-Generation Drug-Eluting...

Presenter: Joshua Loh

October 29, 2013

Presentation TCT 2013

TCT-6. Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results from the ADAPT-DES Registry

Presenter: Usman Baber

October 29, 2013

Presentation TCT 2013

TCT-3. Outcomes in STEMI patients treated with clopidogrel or prasugrel: A propensity adjusted analysis from the INFUSE-AMI Trial

Presenter: Keith Oldroyd

October 29, 2013

Presentation TCT 2013

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Presenter: Laura Mauri

October 29, 2013

Presentation TCT 2013

TCT-9. Racial Disparity With On-Treatment Platelet Reactivity In Patients Undergoing Percutaneous Coronary Intervention

Presenter: Iakshmana Pendyala

October 29, 2013

Presentation TCT 2013

TCT-5. Relationship Between High Platelet Reactivity on Clopidogrel and Outcomes After DES Implantation: Two-Year Results From the ADAPT-DES Study

Presenter: Thomas Stuckey

October 29, 2013

Presentation TCT 2013

TCT-4. Efficacy and Safety of Concurrent Administration of Clopidogrel-loading (600mg) and Prasugrel-loading (60mg) in Patients with Acute ST-Segment Elevation Myocardial...

Presenter: Lorenz Raber

October 29, 2013

Advertisement

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Critical Appraisal and Clinical Implications(3)

Clopidogrel Is Cheap, Effective, and Sufficient for Most!

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Cangrelor Will Be the Answer for Most in the Acute Setting!

Cangrelor Properties: PK, PD and More

BRIDGE Recap

A Patient with a Recent Stent Who is Bleeding

OPTIMIZE: 3-Month DAPT Safe with ZES

EUROMAX: Critical Appraisal and Clinical Implications

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Featured Trial of the Day: EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin vs. Heparin ± Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI...

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-7. Impact Of Early Versus Late Clopidogrel Discontinuation On Stent Thrombosis Following Percutaneous Coronary Intervention With First- And Second-Generation Drug-Eluting...

TCT-6. Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results from the ADAPT-DES Registry

TCT-3. Outcomes in STEMI patients treated with clopidogrel or prasugrel: A propensity adjusted analysis from the INFUSE-AMI Trial

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

TCT-9. Racial Disparity With On-Treatment Platelet Reactivity In Patients Undergoing Percutaneous Coronary Intervention

TCT-5. Relationship Between High Platelet Reactivity on Clopidogrel and Outcomes After DES Implantation: Two-Year Results From the ADAPT-DES Study

TCT-4. Efficacy and Safety of Concurrent Administration of Clopidogrel-loading (600mg) and Prasugrel-loading (60mg) in Patients with Acute ST-Segment Elevation Myocardial...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content